Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity

Clinical trials revealed that systemic administration of B-cell-depleting anti-CD20 antibodies can hold lesion formation in the early relapsing-remitting phase of multiple sclerosis (MS). Throughout the secondary-progressive (SP) course of MS, pathogenic B cells may, however, progressively replicate...

Descripción completa

Detalles Bibliográficos
Autores principales: Lehmann-Horn, Klaus, Kinzel, Silke, Feldmann, Linda, Radelfahr, Florentine, Hemmer, Bernhard, Traffehn, Sarah, Bernard, Claude C A, Stadelmann, Christine, Brück, Wolfgang, Weber, Martin S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184778/
https://www.ncbi.nlm.nih.gov/pubmed/25356419
http://dx.doi.org/10.1002/acn3.71

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184778/
https://www.ncbi.nlm.nih.gov/pubmed/25356419
http://dx.doi.org/10.1002/acn3.71

Ejemplares similares